Dermata Other Current Liab from 2010 to 2024

DRMAW Stock  USD 0.01  0.00  0.00%   
Dermata Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 620.1 K in 2024. During the period from 2010 to 2024, Dermata Therapeutics Other Current Liabilities regression line of quarterly data had mean square error of 33 B and geometric mean of  494,844. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
757.6 K
Current Value
620.1 K
Quarterly Volatility
181.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 213.6 K, Depreciation And Amortization of 8.4 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.29. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Dermata Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Dermata Therapeutics Warrant over the last few years. It is Dermata Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Pretty Stable
   Other Current Liab   
       Timeline  

Dermata Other Current Liab Regression Statistics

Arithmetic Mean529,245
Geometric Mean494,844
Coefficient Of Variation34.23
Mean Deviation105,538
Median500,000
Standard Deviation181,140
Sample Variance32.8B
Range868.1K
R-Value0.26
Mean Square Error33B
R-Squared0.07
Significance0.35
Slope10,438
Total Sum of Squares459.4B

Dermata Other Current Liab History

2024620.1 K
2023757.6 K
2022425.9 K
2021M
2020133.5 K

About Dermata Therapeutics Financial Statements

Dermata Therapeutics investors use historical fundamental indicators, such as Dermata Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities757.6 K620.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Dermata Stock Analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.